
Tislelizumab





islelizumab RATIONALE 304
SCORE
CURATIVE
Overall Survival / Disease-Free Survival / Pathological Complete Response
NON-CURATIVE
Overall Survival
Progression-Free Survival
Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Overall Response Rate / Duration of Response
Overall Survival / Disease-Free Survival / Pathological Complete Response
INFORMATION
Tumour type: Thoracic Malignancies

Therapeutic Indication: Tisleizumab in combination with pemetrexed and platinum-containing ChT is indicated for the first-line treatment of adult patients with NSCLC whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have: locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC

Experimental Arm: Tislelizumab + Pemetrexed + platinum-containing ChT Control Arm: Pemetrexed + platinum-containing ChT

